Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H1 2017

Publisher Name :
Date: 20-Jun-2017
No. of pages: 84

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H1 2017

Summary

According to the recently published report 'Exportin 1 - Pipeline Review, H1 2017'; Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 7 molecules. Out of which approximately 7 molecules are developed by Companies.

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli.

The report 'Exportin 1 - Pipeline Review, H1 2017' outlays comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Hematological Tumor, Malignant Mesothelioma, Melanoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Amyotrophic Lateral Sclerosis, B-Cell Leukemia, Bone Sarcoma, Burkitt Lymphoma, Cervical Cancer, Chondrosarcoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Colorectal Cancer, Duchenne Muscular Dystrophy, Endometrial Cancer, Equine Encephalitis, Fallopian Tube Cancer, Follicular Lymphoma, Gastrointestinal Tract Cancer, Hepatitis C, Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus (HPV) Associated Cancer, Influenzavirus A Infections, Leiomyosarcoma, Leukemias, Liposarcoma, Lymphoma, Mantle Cell Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Multiple Sclerosis, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Renal Cell Carcinoma, Respiratory Syncytial Virus (RSV) Infections, Rheumatoid Arthritis, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Synovial Sarcoma, Systemic Lupus Erythematosus, T-Cell Lymphomas, Thymoma (Thymic Epithelial Tumor), Traumatic Brain Injury, Venezuelan Equine Encephalitis and Waldenstrom Macroglobulinemia.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)

- The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H1 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Overview
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Companies Involved in Therapeutics Development
CanBas Co Ltd
Karyopharm Therapeutics Inc
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug Profiles
KPT-251 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-276 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-350 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KPT-8602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
selinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verdinexor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant Products
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Discontinued Products
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Product Development Milestones
Featured News & Press Releases
Jun 07, 2017: Karyopharm Doses First Patient in Pivotal Phase 3 BOSTON Study Evaluating Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
May 18, 2017: Karyopharm's Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting
Apr 04, 2017: Karyopharm Reports Interim Phase 2b SADAL Data at the 2017 American Association for Cancer Research Annual Meeting
Feb 21, 2017: Stemline Therapeutics Provides Update on SL-801
Dec 15, 2016: Karyopharm and Collaborators Awarded Grant for ALS Research
Dec 05, 2016: Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting
Dec 04, 2016: Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting
Dec 04, 2016: Karyopharm Presents Updated Phase 2b STORM Data at the American Society of Hematology 2016 Annual Meeting
Nov 30, 2016: Karyopharm and the Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought Leaders
Nov 03, 2016: Karyopharm to Present Updated Phase 2b STORM and Phase 1b STOMP Clinical Data at the American Society of Hematology 2016 Annual Meeting
Oct 05, 2016: Karyopharm to Present Updated SIGN Phase 2 Clinical Data at European Society of Medical Oncology 2016 Annual Meeting
Sep 29, 2016: Scientists find lethal vulnerability in treatment-resistant lung cancer
Sep 28, 2016: Karyopharm Publishes Preclinical and Phase 1 Clinical Data for Selinexor in Ovarian Cancer in Clinical Cancer Research Publication
Sep 06, 2016: Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma
Aug 30, 2016: Karyopharm to Host Conference Call with Update on Multiple Myeloma Plans
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Indications, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by CanBas Co Ltd, H1 2017
Pipeline by Karyopharm Therapeutics Inc, H1 2017
Dormant Products, H1 2017
Dormant Products, H1 2017 (Contd..1), H1 2017
Discontinued Products, H1 2017

List of Figures
Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Top 10 Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
  • Global and United States Biobanking In-Depth Research Report 2017-2022
    Published: 20-Oct-2017        Price: US 3190 Onwards        Pages: 120
    The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022. This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Biobanking industry. Major Companies - Thermo Fisher Scientific Inc. (U.S.) - Tecan Group Ltd. ......
  • Global Biobanking Market Research Report 2017-2022 by Players, Regions, Product Types & Applications
    Published: 19-Oct-2017        Price: US 2380 Onwards        Pages: 124
    The global Biobanking market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. This report offers an overview of the market trends, drivers, and barriers with respect to the Biobanking market. It also provides a detailed overview of the market of different regions across United States, Europe, China, Japan, India, Southeast Asia and Others. The report categorizes Biobanking market by By P......
  • Global and Europe Biobanking Market - Analysis and Outlook to 2022
    Published: 19-Oct-2017        Price: US 2960 Onwards        Pages: 130
    This report presents a comprehensive overview of the Biobanking market in Europe, which shares the history data information from 2012 to 2016, and forecast from 2017 to 2022. This report provides a detailed analysis of the market, including its dynamics, structure, characteristics, main players, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in Biobanking industry. This report focuses Global and Europ......
  • 2017-2022 Global and Japan Biobanking Market Analysis Report
    Published: 19-Oct-2017        Price: US 3085 Onwards        Pages: 120
    The global Biobanking market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022. Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%. This report, with focus on top players in the global and Japan, studies the Biobanking market's development status and future trend in the global and ......
  • Global Biobanking Detailed Analysis Report 2017-2022
    Published: 19-Oct-2017        Price: US 3250 Onwards        Pages: 121
    This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Biobanking industry. This report splits Biobanking market By Product and Service, By Sample, which covers the history data information from 2012 to 2016 and forecast from 2017 to 2022. This report focuses Global market, it covers detai......
  • Global and Regional Epidermal Growth Factor (EGF) (CAS 62253-63-8) Market Research Report 2017
    Published: 19-Oct-2017        Price: US 3500 Onwards        Pages: 105
    Summary Epidermal growth factor (EGF) is a growth factor that stimulates cell growth, proliferation, and differentiation by binding to its receptor EGFR. Human EGF is a 6045-Da protein with 53 amino acid residues and three intramolecular disulfide bonds EGF results in cellular proliferation, differentiation, and survival.EGF considerably increases skin cell regeneration. More precisely, they can directly communicate to the skin cells to produce more collagen and elastin, that's wh......
  • China Contract Research Organization (CRO) Industry Report, 2017-2021
    Published: 18-Oct-2017        Price: US 2700 Onwards        Pages: 110
    Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the development of new drugs assisted by CRO firms in recent years, stimulating the progression of global CRO industry which had a market size of USD31.7 billion in 2016. There are more than 1,100 CRO companies around the world, led by Quintiles IMS, Covance, in Ventiv Health, Charles River, Parex......
  • Global Digital PCR (dPCR) Sales Market Report 2017
    Published: 18-Oct-2017        Price: US 4000 Onwards        Pages: 111
    In this report, the global Digital PCR (dPCR) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Digital PCR (dPCR) for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japa......
  • Global Somatostatin Sales Market Report 2017
    Published: 18-Oct-2017        Price: US 4000 Onwards        Pages: 114
    In this report, the global Somatostatin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Somatostatin for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Sout......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs